SFM
TPTX

Sphera Funds Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Sphera Funds Management’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-68,734
Closed -$3.28M – 104
2021
Q4 		$3.28M Buy
+68,734
New +$3.07M 0.36% 66

Other funds holding TPTX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Sphera Funds Management's TPTX Position: Q1 2022 in Review

Sphera Funds Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q1 2022, closing a stake of 68,734 shares — an estimated $3.28M sold.

Sphera Funds Management first reported a position in TPTX in Q4 2021 and held it in 1 quarter. The position peaked at $3.28M in Q4 2021. 155 funds tracked by Wall St. Rank hold TPTX as of Q1 2022.

  • Sphera Funds Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Sphera Funds Management sold 68,734 Turning Point Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $3.28M.
  • Sphera Funds Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Sphera Funds Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $3.28M in Q4 2021.
  • 155 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Sphera Funds Management's 13F filing for Q1 2022, filed 16 May 2022.